| COPDGene (R) 2019: Redefining the Diagnosis of Chronic Obstructive Pulmonary Disease |
18 |
| National and State Estimates of COPD Morbidity and Mortality United States, 2014-2015 |
15 |
| Improvements in Lung Function with Nebulized Revefenacin in the Treatment of Patients with Moderate to Very Severe COPD: Results from Two Replicate Phase III Clinical Trials |
13 |
| The Role of Inhalation Delivery Devices in COPD: Perspectives o Patients and Health Care Providers |
9 |
| Mortality and Exacerbations by Global Initiative for Chronic Obstructive Lung Disease Groups ABCD: 2011 Versus 2017 in the COPDGene (R) Cohort |
8 |
| The Clinical Features of Bronchiectasis Associated with Alpha-1 Antitrypsin Deficiency, Common Variable Immunodeficiency and Primary Ciliary Dyskinesia-Results from the U.S. Bronchiectasis Research Registry |
7 |
| Intrapleural Gene Therapy for Alpha-1 Antitrypsin Deficiency-Related Lung Disease |
7 |
| New Therapeutic Targets for Alpha-1 Antitrypsin Deficiency |
6 |
| Subtypes of COPD Have Unique Distributions and Differential Risk of Mortality |
6 |
| Pulmonary Subtypes Exhibit Differential Global Initiative for Chronic Obstructive Lung Disease Spirometry Stage Progression: The COPDGene (R) Study |
6 |
| Spirometry Measurement of Peak Inspiratory Flow Identifies Suboptimal Use of Dry Powder Inhalers in Ambulatory Patients with COPD |
6 |
| Alpha-1 Antitrypsin Substitution for Extrapulmonary Conditions in Alpha-1 Antitrypsin Deficient Patients |
5 |
| The Effects of a Comprehensive Care Management Program on Readmission Rates After Acute Exacerbation of COPD at a Community-Based Academic Hospital |
5 |
| Intravenous Alpha-1 Antitrypsin Therapy for Alpha-1 Antitrypsin Deficiency: The Current State of the Evidence |
5 |
| Pattern and Adherence to Maintenance Medication Use in Medicare Beneficiaries with Chronic Obstructive Pulmonary Disease: 2008-2013 |
5 |
| Inhalation Technique Errors with Metered-Dose Inhalers Among Patients with Obstructive Lung Diseases: A Systematic Review and Meta-Analysis of U.S. Studies |
4 |
| Race and Gender Disparities are Evident in COPD Underdiagnoses Across all Severities of Measured Airflow Obstruction |
4 |
| Nebulized Versus Dry Powder Long-Acting Muscarinic Antagonist Bronchodilators in Patients With COPD and Suboptimal Peak Inspiratory Flow Rate |
4 |
| Comparing Patients with ZZ Versus SZ Alpha-1 Antitrypsin Deficiency: Findings from AlphaNet's Disease Management Program |
4 |
| Internet Health Behaviors of Patients with Chronic Obstructive Pulmonary Disease and Assessment of Two Disease Websites |
3 |
| Patient-Reported Consequences of Community-Acquired Pneumonia in Patients with Chronic Obstructive Pulmonary Disease |
3 |
| Physiologic Insights from the COPD Genetic Epidemiology Study |
3 |
| Spirometry in Hospitalized Patients with Acute Exacerbation of COPD Accurately Predicts Post Discharge Airflow Obstruction |
3 |
| Endobronchial Coils Versus Lung Volume Reduction Surgery or Medical Therapy for Treatment of Advanced Homogenous Emphysema |
3 |
| Evaluation of Systemic Corticosteroids in Patients With an Acute Exacerbation of COPD and a Diagnosis of Pneumonia |
2 |
| Markers of Dental Health Correlate with Daily Respiratory Symptoms in COPD |
2 |
| Lung, Fat and Bone: Increased Adiponectin Associates with the Combination of Smoking-Related Lung Disease and Osteoporosis |
2 |
| Stem Cell Therapy for COPD: Where are we? |
2 |
| Antioxidants and Chronic Obstructive Pulmonary Disease |
2 |
| Alpha-1 Antitrypsin Therapy for Autoimmune Disorders |
2 |
| Health-Related Quality of Life Improvements in Moderate to Very Severe Chronic Obstructive Pulmonary Disease Patients on Nebulized Glycopyrrolate: Evidence from the GOLDEN Studies |
2 |
| Stability of Frequency of Severe Chronic Obstructive Pulmonary Disease Exacerbations and Health Care Utilization in Clinical Populations |
2 |
| Chronic Bronchitis: Where Are We Now? |
2 |
| Urban-Rural Disparities in Chronic Obstructive Pulmonary Disease Management and Access in Uganda |
2 |
| Efficacy and Safety of Nebulized Glycopyrrolate/eFlow (R) Closed System in Patients with Moderate-to-Very-Severe Chronic Obstructive Pulmonary Disease with Pre-Existing Cardiovascular Risk Factors |
1 |
| Costs of Medical Care Among Augmentation Therapy Users and Non-Users with Alpha-1 Antitrypsin Deficiency in the United States |
1 |
| Revealing Methodological Challenges in Chronic Obstructive Pulmonary Disease Studies Assessing Comorbidities: A Narrative Review |
1 |
| Follow-up Soon After Discharge May Not Reduce COPD Readmissions |
1 |
| Websites, Online Communities and Digital Channels as a Medium to Effectively Educate, Engage and Empower Patients |
1 |
| The Short-term Impact of Symptom-defined COPD Exacerbation Recovery on Health Status and Lung Function |
1 |
| Long-Term Evaluation of the Effects of Aclidinium Bromide on Major Adverse Cardiovascular Events and COPD Exacerbations in Patients with Moderate to Very Severe COPD: Rationale and Design of the ASCENT COPD Study |
1 |
| Marijuana Use Associations with Pulmonary Symptoms and Function in Tobacco Smokers Enrolled in the Subpopulations and Intermediate Outcome Measures in COPD Study (SPIROMICS) |
1 |
| A Novel Approach to Screening for Alpha-1 Antitrypsin Deficiency: Inpatient Testing at a Teaching Institution |
1 |
| Introducing the New COPD Pocket Consultant Guide App: Can A Digital Approach Improve Care? A Statement of the COPD Foundation |
1 |
| A Retrospective Claims Analysis of Dual Bronchodilator Fixed-Dose Combination Versus Bronchodilator Monotherapy in Patients with Chronic Obstructive Pulmonary Disease |
1 |
| Identifying Smoking-Related Disease on Lung Cancer Screening CT Scans: Increasing the Value |
1 |
| Alpha-1 Antitrypsin Deficiency: A Predisposing Factor for the Development of Pulmonary Langerhans Cell Histiocytosis |
0 |
| The COPD Pipeline XXXVIII |
0 |
| Effectiveness of Umeclidinium-Vilanterol for Protocolized Management of Chronic Obstructive Pulmonary Disease Exacerbation in Hospitalized Patients: A Sequential Period Analysis |
0 |
| Journal Club - Asthma/Chronic Obstructive Pulmonary Disease Overlap: Fact or Fiction? |
0 |
